Sichuan Baili Pharmaceutical Co., Ltd.

This study tests a new drug called BL-M07D1, alone or combined with other medicines, as a first treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The goal is to see if these treatments shrink tumors and how safe they are. About 83 a…

This phase 3 study compares a new drug, BL-B01D1, to standard chemotherapy in 418 people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth and extend survival. Participants must be…

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced esophageal cancer that has worsened after initial treatment. About 497 participants will receive either the new drug or one of several chemotherapies. The goal is to see if …

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 432 people with advanced non-small cell lung cancer whose previous targeted therapy (EGFR-TKI) has stopped working. The study compares how long the cancer stays under control and overall survival…

This Phase 3 trial compares a new drug called BL-B01D1 to the standard chemo docetaxel in 698 people with advanced non-small cell lung cancer that has not responded to prior immunotherapy and chemo. The goal is to see if BL-B01D1 helps people live longer. Participants receive eit…

This study tests a new drug called BL-B01D1 against standard chemotherapy in about 383 people with advanced HR+HER2- breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth or improve survival. Participants ar…

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced nasopharyngeal cancer that has not responded to at least two prior treatments. About 386 participants will be randomly assigned to receive either the new drug or a standard …

This study compares a new drug called BL-B01D1 to the standard drug topotecan in 722 adults with small cell lung cancer that has come back after initial treatments. The goal is to see if BL-B01D1 helps people live longer. Participants must have already tried immunotherapy and che…

This study tests an experimental drug called BL-B01D1 in 27 adults with advanced chordoma, a rare bone cancer. The goal is to see if the drug can shrink tumors or slow disease progression. Participants receive the drug intravenously, and researchers monitor safety and effectivene…

This early-phase trial tests an experimental drug called BL-M02D1 in 14 people with advanced non-small cell lung cancer that has not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. It is too soon to know if it will wor…

This early-stage trial is testing a new drug called GNC-035, a special antibody that targets four different signals on cancer cells. It is being given to 33 adults with blood cancers like lymphoma or leukemia that have come back or not responded to other treatments. The main goal…

This early-phase trial is testing an experimental drug called BL-M02D1 in 22 people with advanced gastrointestinal or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at whet…

This study tests a combination of two drugs, SI-B001 and irinotecan, in people with advanced esophageal cancer that has come back or spread. The goal is to see if the combo can shrink tumors and control the disease. About 22 adults who have already tried standard treatments are t…

This early-phase trial tests a new drug called SI-B001, a bispecific antibody that targets two proteins (EGFR and HER3) found on many cancer cells. The study involves about 60 adults with advanced epithelial tumors that cannot be cured or have no standard treatment. The main goal…

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…

This early-stage study tests a new drug called GNC-038 in 12 people with diffuse large B-cell lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the dr…

This early-stage trial is testing a new drug called GNC-035, a tetra-specific antibody designed to attack breast cancer cells in multiple ways. It involves 36 adults with locally advanced or metastatic breast cancer whose disease has worsened after standard treatments. The main g…

This phase II trial tests a new drug called SI-B001 combined with the chemotherapy paclitaxel in 42 adults with recurrent or metastatic head and neck squamous cell carcinoma. Participants have already tried standard treatments like immunotherapy or platinum chemo. The study aims …

This study tests a new drug (SI-B001) combined with a standard pill (osimertinib) in people with advanced non-small cell lung cancer that has stopped responding to previous therapies. About 14 adults will receive the combination to see if it can shrink tumors and control the dise…

This early-phase trial tests a new drug called GNC-038 in 7 people with relapsed or refractory central nervous system lymphoma (lymphoma that has spread to the brain or spine). The drug is a tetra-specific antibody designed to target cancer cells. The main goals are to check safe…

This early-phase trial is testing a new drug called GNC-035, a tetra-specific antibody, in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and other blood cancers. The study aims to find a safe dose and check for side effects. Only 3 participants have been e…

This early-phase study tests a new drug called BL-B01D1 in people with advanced urinary or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and get a first look at whether it might shrink tumors…

This study tests an experimental drug called GNC-038 in people with certain types of lymphoma that have come back or stopped responding to treatment. The main goals are to find safe dose levels and see if the drug can shrink tumors. The trial is for adults aged 18 to 75 with NK/T…

This phase 2 trial tests a drug called SI-B001 in 11 adults with head and neck cancer that has returned or spread after prior treatments like chemotherapy and immunotherapy. The drug is given weekly through an IV. Researchers are checking if it can shrink tumors and how safe it i…

This early-phase study tests a new drug called BL-M02D1 in people with advanced triple negative breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors.…

This study tests a new drug called SI-B001 combined with chemotherapy in 69 adults with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Participants must have a specif…

This early-phase study is testing an experimental drug called GNC-038, a quad-specific antibody designed to attack cancer cells from multiple angles. It is for people with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia who have not responded to other …

This Phase II study tests a new drug called BL-B01D1, given alone or with the tablet osimertinib, in 198 adults with advanced non-small cell lung cancer. The goal is to see if the treatment shrinks tumors and to check for side effects. Participants must have a confirmed diagnosis…